共 50 条
- [11] Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer An Analysis of Data From the I-SPY2 Randomized Clinical TrialJAMA ONCOLOGY, 2021, 7 (11) : 1654 - 1663Symmans, W. FraserYau, ChristinaChen, Yunn-YiBalassanian, RonKlein, Molly E.Pusztai, LajosNanda, RitaParker, Barbara A.Datnow, BrianKrings, GregorWei, ShiFeldman, Michael D.Duan, XiuzhenChen, BeiyunSattar, HusainKhazai, LailaZeck, Jay C.Sams, SharonMhawech-Fauceglia, PauletteRendi, MaraSahoo, SunatiOcal, Idris TolgayFan, FangLeBeau, Lauren GrassoVinh, TuyethoaTroxell, Megan L.Chien, A. JoWallace, Anne M.Forero-Torres, AndresEllis, ErinAlbain, Kathy S.Murthy, Rashmi K.Boughey, Judy C.Liu, Minetta C.Haley, Barbara B.Elias, Anthony D.Clark, Amy S.Kemmer, KathleenIsaacs, ClaudineLang, Julie E.Han, Hyo S.Edmiston, KirstenViscusi, Rebecca K.Northfelt, Donald W.Khan, Qamar J.Leyland-Jones, BrianVenters, Sara J.Shad, SonalMatthews, Jeffrey B.Asare, Smita M.
- [12] Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trialBREAST CANCER RESEARCH AND TREATMENT, 2023, 199 (02) : 281 - 291Parker, Barbara A.Shatsky, Rebecca A.Schwab, Richard B.Wallace, Anne M.Wolf, Denise M.Hirst, Gillian L.Brown-Swigart, LamornaEsserman, Laura J.van 't Veer, Laura J.Ghia, Emanuela M.Yau, ChristinaKipps, Thomas J.
- [13] Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trialNPJ BREAST CANCER, 2020, 6 (01)Wolf, Denise M.Yau, ChristinaWulfkuhle, JuliaBrown-Swigart, LamornaGallagher, Rosa I.Jesus M. Magbanua, MarkO'Grady, NickHirst, GillianAsare, SmitaTripathy, DebuBerry, DonEsserman, LauraChien, A. JoPetricoin, Emanuel F., IIIvan't Veer, Laura
- [14] Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancerCELL REPORTS MEDICINE, 2024, 5 (11)Campbell, Michael J.Wolf, Denise M.Yau, ChristinaBrown-Swigart, LamornaWulfkuhle, JulieGallagher, Isela R.Zhu, ZelosBolen, JenniferVandenberg, ScottHoyt, CliffordMori, HidetoshiBorowsky, AlexanderSit, LauraPerlmutter, JaneAsare, Smita M.Nanda, RitaLiu, Minetta C.Yee, DouglasDemichele, Angela M.Hylton, Nola M.Pusztai, LajosBerry, Donald A.Hirst, Gillian L.Petricoin, Emanuel F.van't Veer, LauraEsserman, Laura
- [15] Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 TrialJAMA SURGERY, 2022, 157 (11) : 1034 - 1041Osdoit, MarieYau, ChristinaSymmans, W. FraserBoughey, Judy C.Ewing, Cheryl A.Balassanian, RonChen, Yunn-YiKrings, GregorWallace, Anne M.Zare, SomayeFadare, OluwoleLancaster, RachaelWei, ShiGodellas, Constantine, VTang, PingTuttle, Todd M.Klein, MollySahoo, SunatiHieken, Tina J.Carter, Jodi M.Chen, BeiyunAhrendt, GretchenTchou, JuliaFeldman, MichaelTousimis, EleniZeck, JayJaskowiak, NoraSattar, HusainNaik, Arpana M.Lee, Marie CatherineRosa, MarilinKhazai, LailaRendi, Mara H.Lang, Julie E.Lu, JaniceTawfik, OssamaAsare, Smita M.Esserman, Laura J.Mukhtar, Rita A.
- [16] Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trialBreast Cancer Research and Treatment, 2023, 199 : 281 - 291Barbara A. ParkerRebecca A. ShatskyRichard B. SchwabAnne M. WallaceDenise M. WolfGillian L. HirstLamorna Brown-SwigartLaura J. EssermanLaura J. van ’t VeerEmanuela M. GhiaChristina YauThomas J. Kipps
- [17] Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical TrialANNALS OF SURGICAL ONCOLOGY, 2025, : 3278 - 3291Boughey, Judy C.Yu, HongmeiSwitalla, KaylaVelle, LadoresLopes, AlexWallace, Anne M.Lancaster, Rachel B.Reyna, Chantal R.Tuttle, Todd M.Jaskowiak, NoraTchou, JuliaRao, RoshniLee, Marie C.Naik, Arpana M.Golshan, MehraArciero, Cletus A.Sauder, Candice A. M.Matsen, Cindy B.Yau, ChristinaEsserman, LauraMukhtar, Rita A.
- [18] Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (03) : 1049 - 1062Esserman, Laura J.Berry, Donald A.Cheang, Maggie C. U.Yau, ChristinaPerou, Charles M.Carey, LisaDeMichele, AngelaGray, Joe W.Conway-Dorsey, KathleenLenburg, Marc E.Buxton, Meredith B.Davis, Sarah E.van't Veer, Laura J.Hudis, CliffordChin, KoeiWolf, DeniseKrontiras, HelenMontgomery, LeslieTripathy, DebuLehman, ConstanceLiu, Minetta C.Olopade, Olufunmilayo I.Rugo, Hope S.Carpenter, John T.Livasy, ChadDressler, LynnChhieng, DavidSingh, BaljitMies, CarolynRabban, JosephChen, Yunni-YiGiri, DilipAu, AlfredHylton, Nola
- [19] Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancerBREAST CANCER RESEARCH AND TREATMENT, 2025, 209 (03) : 487 - 492Rugo, Hope S.Campbell, MikeYau, ChristinaJo Chien, A.Wallace, Anne M.Isaacs, ClaudineBoughey, Judy C.Han, Hyo S.Buxton, MeredithClennell, Julia L.Asare, Smita M.Steeg, KatherineWilson, AmySinghrao, RubyMatthews, Jeffrey B.Perlmutter, JaneFraser Symmans, W.Hylton, Nola M.Demichele, Angela M.Yee, DouglasVan't Veer, Laura J.Berry, Donald A.Esserman, Laura J.
- [20] Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIALTOMOGRAPHY, 2016, 2 (04) : 378 - 387Li, WenArasu, VigneshNewitt, David C.Jones, Ella F.Wilmes, LisaGibbs, JessicaKornak, JohnJoe, Bonnie N.Esserman, Laura J.Hylton, Nola M.